Autolus Therapeutics Ltd (AUTL) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Autolus Therapeutics Ltd stock (AUTL) is currently trading at $1.32. Autolus Therapeutics Ltd PS ratio (Price-to-Sales) is 7.13. Analyst consensus price target for AUTL is $8.99. WallStSmart rates AUTL as Sell.
- AUTL PE ratio analysis and historical PE chart
- AUTL PS ratio (Price-to-Sales) history and trend
- AUTL intrinsic value — DCF, Graham Number, EPV models
- AUTL stock price prediction 2025 2026 2027 2028 2029 2030
- AUTL fair value vs current price
- AUTL insider transactions and insider buying
- Is AUTL undervalued or overvalued?
- Autolus Therapeutics Ltd financial analysis — revenue, earnings, cash flow
- AUTL Piotroski F-Score and Altman Z-Score
- AUTL analyst price target and Smart Rating
Autolus Therapeutics
📊 No data available
Try selecting a different time range
Smart Analysis
Autolus Therapeutics Ltd (AUTL) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Autolus Therapeutics Ltd (AUTL) Key Strengths (2)
78.99% of shares held by major funds and institutions
Trading at 1.38x book value, attractively priced
Supporting Valuation Data
Autolus Therapeutics Ltd (AUTL) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Revenue declining -11.00%, a shrinking business
Premium valuation at 7.1x annual revenue
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Autolus Therapeutics Ltd (AUTL) Detailed Analysis Report
Overall Assessment
This company scores 26/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 2 register as strengths (avg 9.0/10) while 5 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Price/Book. Valuation metrics including Price/Book (1.38) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (7.13) suggest expensive pricing. Growth concerns include Revenue Growth at -11.00%, which may limit upside. Profitability pressure is visible in Return on Equity at -60.60%, Operating Margin at -337.90%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -60.60% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -11.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
AUTL Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
AUTL's Price-to-Sales ratio of 7.13x trades at a deep discount to its historical average of 1433.37x (0th percentile). The current valuation is 100% below its historical high of 9934.44x set in Nov 2018, and 0% above its historical low of 7.13x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~43.7x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Autolus Therapeutics Ltd (AUTL) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Autolus Therapeutics Ltd operates as a stable business with moderate growth and solid fundamentals. Revenue reached 51M with 11% decline year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Spending 55% of revenue (28M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 11% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -83M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 2.00, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Autolus Therapeutics Ltd.
Bottom Line
Autolus Therapeutics Ltd offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Autolus Therapeutics Ltd(AUTL)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T-cell therapies for the treatment of cancer. The company is headquartered in London, the United Kingdom.